WoodTrust Financial Corp Sells 588,232 Shares of Amgen Inc. $AMGN

WoodTrust Financial Corp lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 98.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,402 shares of the medical research company’s stock after selling 588,232 shares during the quarter. WoodTrust Financial Corp’s holdings in Amgen were worth $2,089,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. OLD National Bancorp IN raised its holdings in Amgen by 296.2% during the second quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock valued at $5,027,000 after acquiring an additional 13,460 shares during the period. Atlantic Union Bankshares Corp boosted its stake in shares of Amgen by 165.0% in the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after acquiring an additional 6,627 shares during the period. D.A. Davidson & CO. grew its position in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Davis Capital Management bought a new stake in Amgen during the 3rd quarter valued at approximately $1,841,000. Finally, L2 Asset Management LLC lifted its holdings in Amgen by 50.8% in the 2nd quarter. L2 Asset Management LLC now owns 9,837 shares of the medical research company’s stock worth $2,747,000 after purchasing an additional 3,314 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $330.41 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $346.38. The company has a market capitalization of $177.92 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 2.94 and a beta of 0.45. The firm’s 50-day moving average is $331.56 and its 200 day moving average is $306.01.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the previous year, the business earned $5.58 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 73.57%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AMGN shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Royal Bank Of Canada raised their target price on shares of Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. Guggenheim increased their price objective on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Truist Financial boosted their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Finally, UBS Group upgraded Amgen to a “strong-buy” rating in a report on Wednesday, January 7th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $339.45.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.